Active surveillance for favorable intermediate-risk prostate cancer involves a structured monitoring plan to track disease progression while avoiding or delaying definitive treatment. Patients typically undergo:

-PSA testing every 3–6 months

-Digital rectal exams (DRE) annually

-Multiparametric MRI as needed to assess suspicious areas or guide biopsy

-Prostate biopsy every 1–3 years, or sooner if PSA rises or MRI changes

This strategy is considered in older patients, those with significant comorbidities, or individuals who prioritize maintaining quality of life and want to avoid the potential side effects of surgery or radiation, such as urinary incontinence or sexual dysfunction.